Recombinant Human FGFR-3 Protein(HEK293), C- Fc

Fibroblast Growth Factor Receptor 3 (FGFR3) is a critical receptor involved in various developmental processes, particularly in bone growth and differentiation. Mutations in the FGFR3 gene are associated with several skeletal disorders, including achondroplasia and hypochondroplasia, which lead to disproportionate short stature. In cancer research, aberrant FGFR3 signaling has been implicated in the progression of certain tumors, notably bladder cancer and multiple myeloma, making FGFR3 a potential therapeutic target. Recombinant FGFR3 proteins have become increasingly important for understanding the receptor's biological functions, interactions with ligands, and its role in disease mechanisms. The production of these recombinant proteins facilitates the study of FGFR3's structure-function relationships, helps to identify small molecules or antibodies that can modulate its activity, and supports the development of novel therapeutic strategies aimed at treating FGFR3-related disorders. Advances in molecular cloning and expression systems have enabled researchers to produce high-purity FGFR3 proteins, allowing for detailed functional assays and structural analyses. Such studies are essential not only for elucidating the pathways regulated by FGFR3 but also for the design of targeted drugs that can effectively inhibit or activate this receptor, thereby offering hope for improved treatment options for patients with FGFR3-associated conditions.